These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 1420452)
1. Treatment of patients with advanced cancer using tumor infiltrating lymphocytes transduced with the gene of resistance to neomycin. Favrot MC; Philip T Hum Gene Ther; 1992 Oct; 3(5):533-42. PubMed ID: 1420452 [No Abstract] [Full Text] [Related]
2. Clinical application of retroviral gene transfer in oncology: results of a French study with tumor-infiltrating lymphocytes transduced with the gene of resistance to neomycin. Merrouche Y; Negrier S; Bain C; Combaret V; Mercatello A; Coronel B; Moskovtchenko JF; Tolstoshev P; Moen R; Philip T J Clin Oncol; 1995 Feb; 13(2):410-8. PubMed ID: 7844602 [TBL] [Abstract][Full Text] [Related]
3. The treatment of patients with melanoma using interleukin-2, interleukin-4 and tumor infiltrating lymphocytes. Hum Gene Ther; 1992 Apr; 3(2):167-77. PubMed ID: 1391037 [No Abstract] [Full Text] [Related]
4. Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. Rosenberg SA; Aebersold P; Cornetta K; Kasid A; Morgan RA; Moen R; Karson EM; Lotze MT; Yang JC; Topalian SL N Engl J Med; 1990 Aug; 323(9):570-8. PubMed ID: 2381442 [TBL] [Abstract][Full Text] [Related]
5. Upregulation of tumor necrosis factor-alpha production by retrovirally transduced human tumor-infiltrating lymphocytes using trans-retinoic acid. Treisman J; Hwu P; Yannelli JR; Shafer GE; Cowherd R; Samid D; Rosenberg SA Cell Immunol; 1994 Jul; 156(2):448-57. PubMed ID: 8025957 [TBL] [Abstract][Full Text] [Related]
6. Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts. Heslop HE; Brenner MK; Rooney C; Krance RA; Roberts WM; Rochester R; Smith CA; Turner V; Sixbey J; Moen R Hum Gene Ther; 1994 Mar; 5(3):381-97. PubMed ID: 8018749 [No Abstract] [Full Text] [Related]
7. The treatment of patients with metastatic melanoma and renal cell cancer using in vitro expanded and genetically-engineered (neomycin phosphotransferase) bulk, CD8(+) and/or CD4(+) tumor infiltrating lymphocytes and bulk, CD8(+) and/or CD4(+) peripheral blood leukocytes in combination with recombinant interleukin-2 alone, or with recombinant interleukin-2 and recombinant alpha interferon. Hum Gene Ther; 1992 Aug; 3(4):411-30. PubMed ID: 1326336 [No Abstract] [Full Text] [Related]
8. Simultaneous use of two retroviral vectors in human gene marking trials: feasibility and potential applications. Miller AR; Skotzko MJ; Rhoades K; Belldegrun AS; Tso CL; Kaboo R; McBride WH; Jacobs E; Kohn DB; Moen R Hum Gene Ther; 1992 Dec; 3(6):619-24. PubMed ID: 1482701 [TBL] [Abstract][Full Text] [Related]
9. Retroviral-mediated gene transfer into hematopoietic cells. Kantoff PW; Gillio A; McLachlin JR; Flake AW; Eglitis MA; Moen R; Karlsson S; Kohn DB; Karson E; Zwiebel JA Trans Assoc Am Physicians; 1986; 99():92-102. PubMed ID: 3299988 [No Abstract] [Full Text] [Related]
10. Cancer immunotherapy using tumor-infiltrating lymphocytes. Figlin RA Semin Hematol; 1992 Apr; 29(2 Suppl 1):33-5. PubMed ID: 1535456 [No Abstract] [Full Text] [Related]
11. Increased efficiency of gene transfer with retroviral vectors in neonatal hematopoietic progenitor cells. al-Lebban ZS; Henry JM; Jones JB; Eglitis MA; Anderson WF; Lothrop CD Exp Hematol; 1990 Mar; 18(3):180-4. PubMed ID: 2303110 [TBL] [Abstract][Full Text] [Related]
12. Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer. Rosenberg SA J Clin Oncol; 1992 Feb; 10(2):180-99. PubMed ID: 1732421 [No Abstract] [Full Text] [Related]
13. A retroviral vector system 'STITCH' in combination with an optimized single chain antibody chimeric receptor gene structure allows efficient gene transduction and expression in human T lymphocytes. Weijtens ME; Willemsen RA; Hart EH; Bolhuis RL Gene Ther; 1998 Sep; 5(9):1195-203. PubMed ID: 9930320 [TBL] [Abstract][Full Text] [Related]
15. Genetically marking human cells--results of the first clinical gene transfer studies. Cai Q; Rubin JT; Lotze MT Cancer Gene Ther; 1995 Jun; 2(2):125-36. PubMed ID: 7621260 [TBL] [Abstract][Full Text] [Related]
16. Homing and survival of thymidine kinase-transduced human T cells in NOD/SCID mice. Di Ianni M; Terenzi A; Falzetti F; Bartoli A; Di Florio S; Benedetti R; Venditti G; Alfonsi D; De Ioanni M; Falini B; Tabilio A Cancer Gene Ther; 2002 Sep; 9(9):756-61. PubMed ID: 12189525 [TBL] [Abstract][Full Text] [Related]
17. Gene therapy of cancer. Rosenberg SA Important Adv Oncol; 1992; ():17-38. PubMed ID: 1582673 [No Abstract] [Full Text] [Related]
18. The genetic modification of T cells for cancer therapy: an overview of laboratory and clinical trials. Hwu P; Rosenberg SA Cancer Detect Prev; 1994; 18(1):43-50. PubMed ID: 8162605 [TBL] [Abstract][Full Text] [Related]